UA72317C2 - Противоаритмический препарат на основе глюконовой кислоты - Google Patents
Противоаритмический препарат на основе глюконовой кислоты Download PDFInfo
- Publication number
- UA72317C2 UA72317C2 UA2002097473A UA2002097473A UA72317C2 UA 72317 C2 UA72317 C2 UA 72317C2 UA 2002097473 A UA2002097473 A UA 2002097473A UA 2002097473 A UA2002097473 A UA 2002097473A UA 72317 C2 UA72317 C2 UA 72317C2
- Authority
- UA
- Ukraine
- Prior art keywords
- potassium
- magnesium
- drugs
- antiarrhythmic
- gluconates
- Prior art date
Links
- 239000003416 antiarrhythmic agent Substances 0.000 title abstract description 29
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 title abstract description 14
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 title abstract description 7
- 239000000174 gluconic acid Substances 0.000 title abstract description 7
- 235000012208 gluconic acid Nutrition 0.000 title abstract description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract description 48
- 239000011591 potassium Substances 0.000 abstract description 48
- 229910052700 potassium Inorganic materials 0.000 abstract description 47
- 239000003814 drug Substances 0.000 abstract description 41
- 235000015778 magnesium gluconate Nutrition 0.000 abstract description 41
- 235000013926 potassium gluconate Nutrition 0.000 abstract description 40
- 229960003975 potassium Drugs 0.000 description 47
- 229940079593 drug Drugs 0.000 description 40
- 206010003119 arrhythmia Diseases 0.000 description 37
- 239000000203 mixture Substances 0.000 description 36
- 230000006793 arrhythmia Effects 0.000 description 32
- 239000000243 solution Substances 0.000 description 26
- 230000000694 effects Effects 0.000 description 21
- 230000033764 rhythmic process Effects 0.000 description 20
- 230000003288 anthiarrhythmic effect Effects 0.000 description 19
- 239000011777 magnesium Substances 0.000 description 15
- 229910052749 magnesium Inorganic materials 0.000 description 15
- 229940091250 magnesium supplement Drugs 0.000 description 15
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 14
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 12
- 229960005260 amiodarone Drugs 0.000 description 11
- 229960003035 magnesium gluconate Drugs 0.000 description 11
- 239000001755 magnesium gluconate Substances 0.000 description 11
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 11
- 239000004224 potassium gluconate Substances 0.000 description 10
- 229960003189 potassium gluconate Drugs 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- -1 sulfate anions Chemical class 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 7
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 7
- 229910001626 barium chloride Inorganic materials 0.000 description 7
- 230000036471 bradycardia Effects 0.000 description 7
- 208000006218 bradycardia Diseases 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 230000000069 prophylactic effect Effects 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 6
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 6
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 6
- 229930010555 Inosine Natural products 0.000 description 6
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229940039750 aconitine Drugs 0.000 description 6
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 6
- 230000037005 anaesthesia Effects 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229960003786 inosine Drugs 0.000 description 6
- 229910001425 magnesium ion Inorganic materials 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 208000003663 ventricular fibrillation Diseases 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 5
- 230000003126 arrythmogenic effect Effects 0.000 description 5
- 210000003191 femoral vein Anatomy 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 108700024047 pangamic acid Proteins 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010015856 Extrasystoles Diseases 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 229940097217 cardiac glycoside Drugs 0.000 description 4
- 239000002368 cardiac glycoside Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 4
- 229930002534 steroid glycoside Natural products 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 208000002682 Hyperkalemia Diseases 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229960003144 calcium pangamate Drugs 0.000 description 3
- JWLAOERSRUNGEF-JQVJEGKNSA-L calcium;(2r,3s,4r,5r)-6-[2-(dimethylamino)acetyl]oxy-2,3,4,5-tetrahydroxyhexanoate Chemical compound [Ca+2].CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O JWLAOERSRUNGEF-JQVJEGKNSA-L 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- WRKJRDZZDHCZPS-UHFFFAOYSA-J magnesium;dipotassium;2-aminobutanedioate;2-amino-4-hydroxy-4-oxobutanoate Chemical compound [Mg+2].[K+].[K+].[O-]C(=O)C(N)CC(O)=O.[O-]C(=O)C(N)CC(O)=O.[O-]C(=O)C(N)CC([O-])=O WRKJRDZZDHCZPS-UHFFFAOYSA-J 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 150000008143 steroidal glycosides Chemical class 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 208000014181 Bronchial disease Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- JPXZQMKKFWMMGK-KQYNXXCUSA-K IDP(3-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])([O-])=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 JPXZQMKKFWMMGK-KQYNXXCUSA-K 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- RVSTWRHIGKXTLG-UHFFFAOYSA-N Pangamic acid Natural products CC(C)N(C(C)C)C(N(C(C)C)C(C)C)C(=O)OCC(O)C(O)C(O)C(O)C(O)=O RVSTWRHIGKXTLG-UHFFFAOYSA-N 0.000 description 2
- 206010050106 Paroxysmal arrhythmia Diseases 0.000 description 2
- 206010038669 Respiratory arrest Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229960003234 amiodarone hydrochloride Drugs 0.000 description 2
- 208000008784 apnea Diseases 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- SSVFMICWXDVRQN-UHFFFAOYSA-N ethanol;sodium Chemical compound [Na].CCO SSVFMICWXDVRQN-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229910000358 iron sulfate Inorganic materials 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 229940055705 pangamic acid Drugs 0.000 description 2
- ZQTHOIGMSJMBLM-BUJSFMDZSA-N pangamic acid Chemical compound CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O ZQTHOIGMSJMBLM-BUJSFMDZSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000004108 pentose phosphate pathway Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010047302 ventricular tachycardia Diseases 0.000 description 2
- CTNPHHZPAJYPFO-PDXBGNJTSA-N (3s,5s,8r,9s,10s,13r,14s,17r)-3-[(2r,4s,5r,6r)-5-[(2r,3s,4s,5r,6s)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-5,14-dihydroxy-13-methyl-17-(5-oxo-2h-furan Chemical compound C1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C=O)CC[C@@H](C[C@@]5(O)CC[C@H]4[C@@]3(O)CC2)O[C@H]2C[C@@H]([C@@H]([C@@H](C)O2)O[C@@H]2[C@H]([C@H](O)[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](CO)O2)O)OC)=CC(=O)OC1 CTNPHHZPAJYPFO-PDXBGNJTSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- OXTYVEUAQHPPMV-UHFFFAOYSA-N Alinidine Chemical compound ClC1=CC=CC(Cl)=C1N(CC=C)C1=NCCN1 OXTYVEUAQHPPMV-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000002102 Atrial Premature Complexes Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020669 Hypermagnesaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 102000006391 Ion Pumps Human genes 0.000 description 1
- 108010083687 Ion Pumps Proteins 0.000 description 1
- FHIREUBIEIPPMC-UHFFFAOYSA-N K-Strophanthin-beta Natural products O1C(C)C(OC2C(C(O)C(O)C(CO)O2)O)C(OC)CC1OC(CC1(O)CCC2C3(O)CC4)CCC1(C=O)C2CCC3(C)C4C1=CC(=O)OC1 FHIREUBIEIPPMC-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 231100000605 Toxicity Class Toxicity 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229950010767 alinidine Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003440 anti-fibrillation Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 210000001992 atrioventricular node Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- 229940088540 cordarone Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 201000008865 drug-induced hepatitis Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- UUMGNNQOCVDZDG-UHFFFAOYSA-N falipamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCN1C(=O)C2=CC(OC)=C(OC)C=C2C1 UUMGNNQOCVDZDG-UHFFFAOYSA-N 0.000 description 1
- 229950001443 falipamil Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000457 gallopamil Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229960000259 magnesium asparaginate Drugs 0.000 description 1
- QWLHYYKDLOVBNV-UHFFFAOYSA-L magnesium orotate Chemical compound [Mg+2].[O-]C(=O)C1=CC(=O)NC(=O)N1.[O-]C(=O)C1=CC(=O)NC(=O)N1 QWLHYYKDLOVBNV-UHFFFAOYSA-L 0.000 description 1
- 229960000407 magnesium orotate Drugs 0.000 description 1
- ZHYLJCKTXNWNPJ-CEOVSRFSSA-L magnesium;(2s)-2,4-diamino-4-oxobutanoate Chemical compound [Mg+2].[O-]C(=O)[C@@H](N)CC(N)=O.[O-]C(=O)[C@@H](N)CC(N)=O ZHYLJCKTXNWNPJ-CEOVSRFSSA-L 0.000 description 1
- KLISBMUDTJHGSP-AIDJSRAFSA-K magnesium;potassium;(2s)-2-amino-4-hydroxy-4-oxobutanoate;2-amino-4-hydroxy-4-oxobutanoate Chemical compound [Mg+2].[K+].[O-]C(=O)C(N)CC(O)=O.[O-]C(=O)C(N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O KLISBMUDTJHGSP-AIDJSRAFSA-K 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- GAQAKFHSULJNAK-UHFFFAOYSA-N moricizine hydrochloride Chemical compound [Cl-].C12=CC(NC(=O)OCC)=CC=C2SC2=CC=CC=C2N1C(=O)CC[NH+]1CCOCC1 GAQAKFHSULJNAK-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 208000012404 paroxysmal familial ventricular fibrillation Diseases 0.000 description 1
- 208000008510 paroxysmal tachycardia Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229940069337 potassium orotate Drugs 0.000 description 1
- DHBUISJCVRMTAZ-UHFFFAOYSA-M potassium;2,4-dioxo-1h-pyrimidine-6-carboxylate Chemical compound [K+].[O-]C(=O)C1=CC(=O)NC(=O)N1 DHBUISJCVRMTAZ-UHFFFAOYSA-M 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000018406 regulation of metabolic process Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000894 saliuretic effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к медицине, в частности к противоаритмическому препарату на основе глюконовой кислоты, в частности глюконатов калия и/или магния.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2002097473A UA72317C2 (ru) | 2002-09-16 | 2002-09-16 | Противоаритмический препарат на основе глюконовой кислоты |
| PCT/UA2003/000001 WO2004024135A1 (en) | 2002-09-16 | 2003-01-04 | Antiarrythmic agent |
| AU2003228204A AU2003228204A1 (en) | 2002-09-16 | 2003-01-04 | Antiarrythmic agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2002097473A UA72317C2 (ru) | 2002-09-16 | 2002-09-16 | Противоаритмический препарат на основе глюконовой кислоты |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA72317C2 true UA72317C2 (ru) | 2005-02-15 |
Family
ID=34271539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002097473A UA72317C2 (ru) | 2002-09-16 | 2002-09-16 | Противоаритмический препарат на основе глюконовой кислоты |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2003228204A1 (ru) |
| UA (1) | UA72317C2 (ru) |
| WO (1) | WO2004024135A1 (ru) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4778677A (en) * | 1981-07-09 | 1988-10-18 | Ebbesen Gerald K | Method for treatment of nicotine craving |
| US6033653A (en) * | 1990-07-03 | 2000-03-07 | Antoun; Jacques | Shampoo products comprising starch, a compound comprising boron, a compound comprising zinc, and water |
| RU2025973C1 (ru) * | 1992-02-10 | 1995-01-09 | Научно-производственное предприятие "Биофарм" | Раствор для консервации живых органов |
| US5612061A (en) * | 1994-10-14 | 1997-03-18 | Rabkin; Simon W. | Composition and method for the treatment of premenstrual syndrome |
| US5939394A (en) * | 1996-01-18 | 1999-08-17 | Fleming & Company | Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections |
| CA2244117A1 (en) * | 1996-01-25 | 1997-07-31 | William B. Weglicki | Intravenous magnesium gluconate for treatment of conditions caused by excessive oxidative stress due to free radical distribution |
-
2002
- 2002-09-16 UA UA2002097473A patent/UA72317C2/ru unknown
-
2003
- 2003-01-04 WO PCT/UA2003/000001 patent/WO2004024135A1/en not_active Application Discontinuation
- 2003-01-04 AU AU2003228204A patent/AU2003228204A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004024135A1 (en) | 2004-03-25 |
| AU2003228204A1 (en) | 2004-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Honerjäger | Pharmacology of bipyridine phosphodiesterase III inhibitors | |
| JP2945718B2 (ja) | 冷蔵庫温度で安定なホリニン酸塩水溶液並びにその製造方法 | |
| Knight et al. | Amelioration of cisplatin‐induced acute renal failure with 8‐cyclopentyl‐1, 3‐dipropylxanthine | |
| BR112020019325A2 (pt) | Método de tratamento de doença fibrótica | |
| US4115576A (en) | Compositions and method of employing the same for inhibiting alcohol intoxication | |
| KINSEY et al. | Turnover of total carbon dioxide in the aqueous humors and the effect thereon of acetazolamide | |
| WO2020077300A1 (en) | Methods for monitoring tumor lysis syndrome | |
| BR112021002387A2 (pt) | métodos para retardo de ocorrência de diabetes tipo 2 de início recente e para redução da progressão e tratamento de diabetes tipo 2 | |
| JP2009501734A (ja) | 癌の治療方法 | |
| US4963559A (en) | Method of treating cancer and cancer metastasis | |
| WO2016203468A1 (en) | Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof | |
| ROBERTS et al. | Pharmacological evidence for the importance of catecholamines in cardiac rhythmicity | |
| Melville et al. | General systemic effects and electrocardiographic changes following injections of digitalis glycosides into the lateral ventricle of the brain | |
| RU2223759C1 (ru) | Антиаритмический препарат | |
| UA72317C2 (ru) | Противоаритмический препарат на основе глюконовой кислоты | |
| KOUNENIS et al. | Inhibition of acetylcholinesterase by the H2-receptor antagonist nizatidine | |
| Nayler | The pharmacological protection of the ischaemic heart: the use of calcium and beta-adrenoceptor antagonists | |
| CA3154524A1 (en) | Methods and compositions for treating sickle cell disease with a ferroportin inhibitor (vit-2763) | |
| AU713030B2 (en) | Method of adjusting the circadian rhythm of a mammal | |
| Wang et al. | Hypoxic pulmonary hypertension (HPH) and iptakalim, a novel ATP‐sensitive potassium channel opener targeting smaller arteries in hypertension | |
| Hill et al. | Vasoactive intestinal polypeptide antagonists attenuate vagally induced tachycardia in the anesthetized dog | |
| US7863255B2 (en) | Methods of administering antitumor agent comprising deoxycytidine derivative | |
| Elkady et al. | Magnesium in intensive care unit: a review | |
| Polumbo et al. | The antiarrhythmic effect of lithium chloride for experimental ouabain-induced arrhythmias | |
| HU225988B1 (en) | Use of cytidine-phosphocholine for producing pharmaceutical compositions for diabetic neuropathy |